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Abstract: Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with 
metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among 
them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease. 
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Background
Colorectal cancer (CCR) is the third-leading cause of 
cancer-related deaths worldwide, with over 500,000 
deaths occurring worldwide each year.1
More  than  35%  of  CCR  patients  present  with 
metastases  at  diagnosis  and  require  systemic 
  chemotherapy.  Treatment  combinations,  including 
fluorouracil, leucovorin, irinotecan, oxaliplatin and 
bevacizumab, have increased the survival rates of 
these patients.2–4
Despite the results achieved with these agents, most 
patients will experience a disease relapse. Therefore, 
there is an urgent need to develop new strategies to 
aid this challenging patient population.
Recently, a role has been established for the epi-
dermal growth factor receptor (EGFR) signal trans-
duction pathway in the development of a subset of 
epithelial  tumors.5  EGFR  is  involved  in  multiple 
cellular  proliferation  processes,  including  growth, 
differentiation,  migration,  and  apoptosis.  EGFR 
overexpression has been shown to predict tumor pro-
gression6 in colorectal cancer and is overexpressed in 
25%–77% of these tumors. EGFR is often associated 
with a worse prognosis.7
In  recent  years,  many  EGFR-targeted  agents 
have  been  developed.  The  two  agents  that  have 
demonstrated the best responses are two monoclo-
nal  antibodies  directed  against  EGFR:  cetuximab 
and panitumumab (known as anti-EGFR therapy or 
EGFR inhibitors). These antibodies have presented 
high response rates when administered with chemo-
therapy. Cetuximab is a chimeric anti-EGFR mono-
clonal  antibody  that  has  demonstrated  antitumor 
activity in patients with colorectal cancer.   However, 
this  antibody’s  murine  component  is  a  potential 
source of toxicity and immunogenicity. Due to this, 
there  has  been  a  considerable  amount  of  research 
aimed at eliminating this toxicity. As a result, a new 
agent was developed: panitumumab, a fully human 
IgG2 monoclonal antibody that is highly selective for 
EGFR. The antibody can block EGFR-ligand binding 
and cause internalization of the receptor, resulting in 
the inhibition of tumor growth.8
Several studies have indicated the benefits of the 
addition of panitumumab to metastatic colorectal can-
cer (mCRC) treatment. In this review, we will sum-
marize these studies and update the new indications 
of panitumumab treatment in this setting.
pharmacodynamic  
and Pharmacokinetic Profiles
Panitumumab  is  a  recombinant,  fully  human 
IgG2 monoclonal antibody with a high affinity for 
EGFR.9  Panitumumab  EGFR  binding  causes  rapid 
internalization  of  the  EGFR,  inducing  apoptosis 
and  reducing  cell  proliferation  and  the  production 
of  proinflammatory  cytokines.  Panitumumab  also 
reduces  EGFR  and  VEGF  (vascular  endothelial 
growth   factor) expression.10
The pharmacokinetics of panitumumab adminis-
tered at dosages of 1.0, 1.5, 2.0 or 2.5 mg/kg/week 
have been examined in patients with renal cancer,11 
but study data examining dosages of 6 mg/kg every 
2 weeks and 9 mg/kgr every 3 weeks in solid tumors 
(including  colorectal  cancers)  are  also  available.12 
In fact, the standard dosage is 6 mg/kgr every 2 weeks, 
administered as a 60-minute intravenous infusion. The 
antibody’s elimination half-life is 7.5 days, and it has 
a mean clearance of 4.9 ml/kg/day. The most frequent 
treatment-emergent  adverse  events  are  erythema, 
dermatitis  acneiform,  pruritus,  hypomagnesemia, 
skin exfoliation, fatigue, paronychia, abdominal pain, 
anorexia, nausea, diarrhea, rash and skin fissures.
Several phase I studies have evaluated the safety 
profile  and  optimal  dosing  of  panitumumab.  In  a 
phase I trial evaluating patients with several types of 
solid tumors, the optimum weekly dose was deter-
mined  to  be  2.5  mg/kg.13  Moreover,  two  different 
dosing intervals were studied in the same trial. The 
results indicated that a dose of 6 mg/kg every 2 weeks 
or 9 mg/kg every 3 weeks resulted in similar toxicity 
profiles as the weekly schedule of administration.14 
The most common adverse events reported in phase I 
trials were fatigue, anorexia and skin toxicity, such as 
rash and acneiform dermatitis, with an overall inci-
dence of grade 3 or 4 adverse events of 30% and 7%, 
respectively. Regarding antitumor activity in patients 
with  mCRC,  13%  of  patients  achieved  a  partial 
response and 23% of patients had stable disease.15 No 
dose-limiting toxicities, reported infusion reactions 
or deaths occurred. Similarly, no anti-panitumumab 
antibodies were detected.16
Therapeutic Efficacy
Several recent studies have shown the efficacy of pan-
itumumab in the treatment of mCRC (Tables 1 and 2). 
The most important studies will be summarized here.panitumumab treatment in metastatic colorectal cancer
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Table 1. phase II trials.
n eGFR  
expression
pmab dose Treatment ORR (cR + pR) pFs (weeks) Os (months)  Ref.
WT MT WT MT WT MT
203 #1% 6 mg/kg/2 weeks Monotherapy 9% 9% 15 71 13.5 7.25 15
52 $1% 6 mg/kg/2 weeks Monotherapy 13% 13% 8 8 7.4 7.4 16
116 NA 6 mg/kg/2 weeks FOLFIrI ± pmab 23%  16% 23 19 12.5 7.75 38
Abbreviations: pmab, panitumumab; Orr, overall response rate; Cr, complete response; pr, partial response; wT, wild type; MT, mutant type; pFS, 
progression-free survival; OS, overall survival.
panitumumab monotherapy
The therapeutic efficacy of intravenous panitumumab 
monotherapy in patients with chemotherapy-  refractory 
metastatic  colorectal  rectal  has  been  assessed  in  a 
phase III trial conducted by Van Cutsem et al17 a later 
extension,18 and two phase II trials.19,20
phase II trials
In a multicenter US study, chemotherapy refractory 
patients with metastatic colorectal cancer treated with 
panitumumab every 2 weeks (n = 203) were studied. 
KRAS status was determined in 171 patients. The 
median  progression-free  survival  (PFS)  was  15.0 
vs. 7.1 weeks for wild-type (WT) and mutant (MT) 
KRAS, respectively, and the median overall survival 
(OS) was 54.0 versus 29.1 weeks, respectively. The 
second phase II trial was conducted with Japanese 
patients  (n  =  52)  who  had  chemotherapy  refrac-
tory metastatic colorectal cancer. Panitumumab was 
administered at 6 mgr/kgr every 2 weeks to achieve 
an  objective  response  in  13%  of  patients  (partial 
responses) and in 33% with stable disease.
Comparative phase III trial: panitumumab 
versus Best Supportive Care (BSC)
This was a randomized, open-label phase III study 
of 463 patients with positive EGFR tumor cell stain-
ing  and  radiologically  documented  disease  pro-
gression  after  two  (63%)  or  three  (37%)  lines  of 
  chemotherapy. Patients were randomly assigned to 
receive  panitumumab  6  mgr/kgr  every  two  weeks 
plus BSC (n = 231) or BSC alone (n = 232). The 
primary end point was PFS, and the secondary end-
points  included  best  objective  response,  OS  and 
  tolerability. KRAS mutational status was determined 
in 208 patients from the panitumumab group and in 
219 patients from the BSC group, and post hoc analy-
ses were conducted with stratification for WT KRAS 
and MT KRAS. In this study, panitumumab reduced 
the relative   progression rate by 46% (HR 0.54, 95% 
CI 0.44–0.66, P , 0.0001). This improvement in PFS 
was also observed in the non-responder patients (HR 
0.63, 95% CI 0.52–0.77, P , 0.0001). The improve-
ment in PFS was evident from week 8 and persisted 
until week 32, with a median PFS time of 8 weeks 
being observed for patients receiving panitumumab 
plus  BSC  compared  with  7.3  weeks  for  patients 
receiving BSC alone. As expected, this improvement 
in PFS with panitumumab versus BSC was greater 
in patients with WT KRAS than in those with MT 
KRAS  (P  ,  0.0001).  Moreover,  all  of  the  partial 
responses were achieved by patients with WT KRAS 
(17%), and no responders were found among patients 
with MT KRAS. The median response duration was 
17 weeks, and stable disease was achieved by 34% of 
panitumumab recipients. Overall, 176 patients who 
had been randomly assigned to the BSC group and 
experienced  a  progression  received  panitumumab 
under the crossover protocol. The differences in OS 
were not observed in this study (HR = 1) because of 
the high rate of crossover of the BSC patients, which 
confounded the survival data. To evaluate this cross-
over effect, an open-label extension study evaluated 
the  176  patients  who  had  progressed  to  BSC  and 
started  treatment  with  panitumumab.  In  this  new 
study, the median PFS was 9.4 (95% CI 8.0–13.4), 
and the median OS was 6.3 (95% CI 5.1–6.8 months), 
similar findings to those previously described in the 
phase III trial.
Results  from  all  these  studies  indicate  that  the 
use  of  panitumumab  results  in  a  clinically  signifi-
cant  improvement  in  PFS  in  mCRC  patients  that 
harbored  WT  KRAS  tumors.  Panitumumab  has 
also been shown to improve the clinical benefit in 
patients  with  stable  disease.  Therefore,  the  use  of 
panitumumab monotherapy should be considered for 
those  mCRC  patients  who  have  progressed  previ-
ously to fluoropyrimidine, oxaliplatin and irinotecan López-Gómez et al
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  chemotherapy-based regimens and harbor WT KRAS 
tumors. These promising results with panitumumab 
monotherapy treatment have led to several trials that 
studied the benefits of panitumumab in combination 
with chemotherapy. Despite these good results, we 
have also seen that panitumumab only benefits a sub-
group of patients. Therefore, the question becomes 
the following: which patients are most likely to ben-
efit from the antibody? We discuss that question in 
the next chapter.
predictive factors
The results from the previous studies have shown that 
panitumumab as a monotherapy agent presents different 
response  rates  depending  on  tumor  characteristics. 
Thus, we need to select the patients that are most likely 
to benefit from anti-EGFR therapy. A selection prior 
to treatment could avoid treatment-related toxicities, 
lack of tumor response and wasted resources.
The identification of valid predictive markers of 
response should be imperative prior to the election 
of  a  therapy.  EGFR  monoclonal  antibodies  appear 
to benefit only certain patients. Therefore, we need 
to  establish  validated  predictive  markers.  At  this 
point, the predictive role of EGFR expression, KRAS 
mutation status and skin toxicity have been widely 
studied.
EGFr expression
Traditionally, the determination of EGFR expression 
as  determined  by  immunofluorescence  in  situ 
hybridization (FISH) was performed prior to the start 
of anti-EGFR treatment. In fact, some studies have 
shown a significant association between the responses 
to  this  targeted  therapy  and  an  increase  in  tumor 
EGFR  gene  copy  number.21  Similarly,  in  another 
pivotal phase III comparative trial of 58 patients who 
received panitumumab plus BSC, the presence of an 
increased EGFR gene copy number, as determined by 
FISH, was predictive of a response to panitumumab. 
In  this  study,  patients  presenting  an  EGFR  gene 
copy number $2.5/nucleus had significantly longer 
PFS (P = 0.0039) and overall survival (P = 0.014).22 
Nevertheless, the use of this marker as a predictive 
factor remains controversial. Results from other studies 
indicate that the level of membrane EGFR staining is 
a poor predictor of response. In a multicenter phase II 
study in which 148 patients received panitumumab panitumumab treatment in metastatic colorectal cancer
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treatment  after  prior  chemotherapy  failure,  tumor 
EGFR  expression  was  assessed,  and  patients  with 
high (.10% EGFR intensely staining cells) or low 
(,10%  EGFR  intensely  staining  cells)  expression 
demonstrated a similar median time to PFS (14 weeks) 
and median survival time (8.6 months).23
Thus, the predictive role of EGFR staining remains 
in doubt and cannot be used as a patient selection tool 
for anti-EGFR therapy in colorectal cancer patients.
KrAS mutation status
RAS proteins belong to a superfamily of GTP-binding 
proteins that play an important role in the transduc-
tion of EGFR signals,24 as the stimulation of EGFR 
causes  activation  of  RAS  proteins.  Unfortunately, 
mutations in KRAS genes occur frequently in human 
cancers (.30% in colorectal cancers). When these 
mutations  occur,  they  alter  downstream  signaling, 
even if the EGFR receptor is silenced by anti-EGFR 
monoclonal antibodies.25 In the literature, we found 
several retrospective studies that have reported the 
lack of benefit of the anti-EGFR cetuximab in MT 
KRAS tumors.26 Similar results have been reported 
for panitumumab. Amado et al assessed the predictive 
role of KRAS in panitumumab treatment in a phase III 
randomized trial.27 In this study, 462 patients were 
randomized to panitumumab plus BSC versus BSC 
alone, and KRAS status was determined in almost all 
patients (92%). The PFS achieved with panitumumab 
in patients harboring WT KRAS tumors was signifi-
cantly   longer (HR 0.45, P , 0.0001) than in patients 
with MT KRAS tumors in which panitumumab treat-
ment did not demonstrate any benefit at all (response 
rates  to  panitumumab  were  17%  for  WT  patients 
and 0% for MT patients, respectively). Based on the 
results from this study, panitumumab is only approved 
for KRAS WT tumors, and RAS testing is mandatory 
prior to the initiation of this treatment. Moreover, the 
results from the PRIME study,27 which are discussed 
below, confirmed the importance of KRAS as a pre-
dictive biomarker of efficacy for anti-EGFR mono-
clonal antibody therapy. In this study, and in keeping 
with the trials that were just discussed, the addition of 
panitumumab in the mutated KRAS group resulted in 
a lower PFS. The phase III trial, which demonstrated 
the benefits of panitumumab addition to FOLFIRI in 
second-line therapy, also confirmed the usefulness of 
KRAS mutational status as a predictive biomarker in 
this setting.32 Interestingly, in contrast to its important 
role as a predictive marker for anti-EGFR therapy, 
KRAS has not been shown to be a prognostic bio-
marker in this setting.
Despite these achievements, in daily practice, cer-
tain patients with WT tumors do not respond to pani-
tumumab therapy. In fact, only 30%–40% patients 
who do not respond to anti-EGFR therapy harbor MT 
KRAS tumors. Therefore, there has been an effort to 
identify other genetic determinants of primary resis-
tance to anti-EGFR therapy. Results from recent stud-
ies indicate that mutations in other molecules that 
belong to the EGFR signaling pathways can contrib-
ute to this lack of sensitivity to anti-EGFR therapy.28 
One of these molecules is BRAF, which acts in the 
downstream  pathway  of  EGFR,  similar  to  KRAS. 
This activity has been demonstrated in a retrospec-
tive study by Di Nicolantonio et al. These research-
ers assessed KRAS and BRAF mutational status in 
113 patients who had received treatment with cetux-
imab or panitumumab. None of the BRAF-mutated 
patients  responded  to  treatment  with  anti-EGFR 
antibodies, whereas none of the responders carried 
a  BRAF  mutation  (P  =  0.029).  Moreover,  BRAF-
mutated  patients  had  significantly  shorter  progres-
sion-free survival (P = 0.011) and overall survival 
(P , 0.0001) than WT patients.29
Therefore, it appears that patients harboring MT 
BRAF  tumors  are  also  refractory  to  panitumumab 
treatment, but further prospective studies are required 
to confirm this observation.
Skin toxicity
Skin-related toxicities are the most common adverse 
events reported for the majority of EGFR inhibitors,30 
and the efficacy of panitumumab treatment has been 
associated with skin rash severity, as well. Van Cutsem 
et al demonstrated that the incidence of skin toxicity in 
panitumumab-treated patients is dose-related. In their 
study, it was shown than a greater PFS duration (HR 
0.62, 95% CI 0.44–0.88) and a greater overall survival 
(HR 0.59, 95% CI 0.42–0.85) was correlated with a 
more severe rash (grades 2–4 versus 1).17 In addition, 
86% of responders had grade 2–3 rashes versus 14% of 
responders with grade 1 rashes. Even though skin rash 
appears to be a marker of the drug activity and associ-
ated with clinical benefit, skin rash may also develop 
in patients who do not benefit from treatment at all; López-Gómez et al
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therefore, it cannot be used for selection of therapy 
discontinuation.  A  more  thorough  investigation  of 
this topic is being developed. In the PRIME study 
(see below), an association between skin toxicity and 
efficacy was also observed, and additional analyses 
are currently underway to determine the importance 
of this type of toxicity as a predictive factor.
Apart  from  skin  toxicity  (including  erythema, 
acneiform dermatitis, pruritus, skin exfoliation, rash, 
skin  fissures,  dry  skin  and  acne),  there  are  other 
important adverse events associated with panitumumab 
treatment.  The  most  frequently  reported  adverse 
events are hypomagnesemia (39%), paronychia (25%), 
fatigue (26%), abdominal pain (25%), nausea (23%) 
and diarrhea (21%). The most serious adverse events 
observed  were  pulmonary  fibrosis,  infection  and 
  septic death secondary to severe dermatologic toxicity, 
infusion reactions, abdominal pain, hypomagnesemia, 
nausea, vomiting and constipation (Vectibix®).
Based on the promising results achieved by pani-
tumumab monotherapy in the first-line treatment of 
metastatic colorectal cancer (mCRC), various combi-
nation regimes with chemotherapy agents have been 
developed  and  studied. Two  of  these  studies  were 
published  last  year  and  indicated  a  relevant  clini-
cal benefit when panitumumab was combined with 
chemotherapy: the PRIME study of first-line treat-
ment31 and a second-line therapy randomized study.32 
In  contrast,  panitumumab  in  combination  with  the 
anti-VEGF bevacizumab has been shown to result in 
increased toxicity and shortened PFS.33
panitumumab combination regimens
Combination with bevacizumab  
and oxaliplatin-irinotecan chemotherapy:  
the pACCE (panitumumab Advanced Colorectal 
Cancer Evaluation) study33
This study was a randomized, open-label multicenter, 
phase IIIB trial designed to evaluate the contribution 
of panitumumab to bevacizumab and chemotherapy 
for  first-line  treatment  of  mCRC.  PFS  was  the 
primary  end  point.  The  secondary  end  points 
included objective response rate (RR), OS and safety. 
Overall, 1053 patients were enrolled into one of two 
cohorts:  bevacizumab  plus  fluorouracil,  leucovorin 
and oxaliplatin-based chemotherapy or bevacizumab 
plus a fluorouracil, leucovorin and irinotecan-based 
chemotherapy. The patients were randomly assigned 
to receive concomitant panitumumab or no additional 
treatment.
PFS was significantly worse in the panitumumab 
arm (HR 1.44, 95% CI, 1.13–1.85, P = 0.004). The 
median PFS was 8.8 months (95% CI, 8.3–9.5 months) 
for  the  panitumumab  arm  versus  10.5  months 
(95% CI, 9.4–12.0 months) for the control arm. Due 
to these results, an unplanned interim analysis of sur-
vival was performed. The median OS was 19.4 months 
for the panitumumab group and 24.5 months for con-
trol group in the oxaliplatin chemotherapy arm. In the 
irinotecan chemotherapy cohort, the median OS was 
20.7 months for the panitumumab arm and 20.5 for 
the control arm.   Interestingly, RR was similar between 
the panitumumab and control arms in both chemother-
apy cohorts (46% and 48%, respectively). The safety 
analyses indicated that in both cohorts, more patients 
experienced grade 3 or higher adverse events (AEs) 
in the panitumumab arm than in the control arm (90% 
versus 77% in the oxaliplatin cohort and 90% versus 
63% in the irinotecan cohort). As expected, skin toxic-
ities were the most common grade 3 events, but other 
AEs occurring more frequently in the panitumumab 
arms  included  diarrhea,  dehydration,  hypomag-
nesemia,  infections  and  pulmonary  embolism.  The 
exact explanation for this toxicity is unknown, but it is 
thought that it was exacerbated by dual-pathway inhi-
bition of the EGFR and by pharmacokinetic interac-
tions between the chemotherapy and antibodies.
In conclusion, the combination of panitumumab 
with bevacizumab and chemotherapy resulted in a 
decrease in PFS and is related to an increase in seri-
ous toxicity. Therefore, the combination is not recom-
mended in daily clinical practice.
Combination with oxaliplatin-based 
chemotherapy: the prIME study
First-line  therapy.  The  PRIME  (Panitumumab 
Randomized  Trial  in  Combination  with 
Chemotherapy  for  Metastatic  Colorectal  Cancer  to 
Determine Efficacy) was an open-label, multicenter, 
phase III trial. This study compared the efficacy of 
panitumumab-FOLFOX4  (oxaliplatin  85  mgr/m2, 
folinic  acid  200  mgr/m2,  5-flurouracil  400  mgr/m2 
bolus + 600 mgr/m2/22 hours on day 1 plus the same 
doses of 5-flurouracil on day 2) with FOLFOX4 alone 
in patients with previously untreated mCRC according 
to  tumor  KRAS  status.31  Overall,  1183  patients panitumumab treatment in metastatic colorectal cancer
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were  randomized.  Panitumumab  was  administered 
intravenously over 1 hour at 6 mgr/kgr every 2 weeks 
before chemotherapy. KRAS testing was performed in 
all patients. PFS was the primary end point, and OS 
was the secondary end point.
In the WT subgroup, median PFS was 9.6 months 
(95%  CI,  9.2–11.1  months)  for  panitumumab-
FOLFOX4 and 8.0 months (95% CI, 7.5–9.3 months) 
for  FOLFOX4  alone.  In  the  MT  KRAS  subgroup, 
median  PFS  was  7.3  months  (95%  CI,  6.3–8.0 
months) for panitumumab-FOLFOX4 and 8.8 months 
(95% CI, 7.7–9.4 months) for FOLFOX4. In the WT 
KRAS  subgroup,  the  median  OS  was  23.9  months 
(95%  CI,  20.3–28.3  months)  for  panitumumab-
FOLFOX4 and 19.7 months (95% CI, 17.6–22.6 months) 
for FOLFOX4. The HR was 0.83 (95% CI, 0.67–1.02, 
P  =  0.072),  favoring  the  panitumumab-FOLFOX4 
arm.  In  the  mutated  KRAS  subgroup,  the  median 
OS  was  15.5  months  (95%  CI,  13.1–17.6  months) 
for  panitumumab-FOLFOX4  and  19.3  months 
(95% CI, 16.5–21.8) for FOLFOX4 (HR = 1.24, 95% 
CI 0.98–1.57, P = 0.068).
The  PRIME  is  the  first  study  that  evaluated  the 
benefits of adding panitumumab treatment to first-line 
FOLFOX chemotherapy regimen, and in addition, pro-
spectively evaluated KRAS status. The study indicated 
that the addition of panitumumab to oxaliplatin-based 
chemotherapy results in an increased PFS for patients 
with WT KRAS tumors. Interestingly, the difference in 
median OS, although not statistically significant, also 
favored patients with WT KRAS. Even responses were 
more  frequent  in  the  panitumumab-chemotherapy 
group, although resection rates were similar.
The results observed in WT patients in the PRIME 
study are consistent with those seen in two other first-
line  studies  examining  cetuximab  chemotherapy, 
although  in  the  other  studies,  KRAS  status  was 
analyzed retrospectively.34,35 To date, the only anti-
EGFR  approved  for  mCRC  in  combination  with 
chemotherapy is cetuximab, but similar clinical benefit 
is achieved with panitumumab in the treatment of this 
disease. The 4.2 month benefit in median OS observed 
in the PRIME study in the WT KRAS population, 
although not statistically significant, is similar to the 
3.5 month benefit in median OS reported in the phase III 
CRYSTAL (Cetuximab Combined with   Irinotecan in 
First Line Therapy for Metastatic   Colorectal   Cancer) 
trial  in  which  cetuximab  was  added  to    first-line 
irinotecan-based  chemotherapy.36  In  contrast,  the 
addition of cetuximab to first-line oxaliplatin-based 
chemotherapy does not improve OS or PFS, as has 
been  highlighted  in  the  recently  reported  Medical 
Research Council COIN (Continuous Chemotherapy 
versus  Intermittent  Chemotherapy)  trial.37  As  a 
result, panitumumab instead of cetuximab should be 
considered in first-line WT patients.
The efficacy in the WT KRAS population in the 
PRIME study is similar to that reported in studies that 
included bevacizumab in first-line treatment.38 In fact, 
to elucidate which is the best treatment option for first-
line WT patients (bevacizumab vs. anti-EGFR), there 
is a currently ongoing study aimed at estimating the 
treatment effect on PFS of panitumumab compared 
to bevacizumab in combination with FOLFOX6 che-
motherapy as first-line therapy for mCRC (the PEAK 
study).39 The primary outcome is PFS, and the esti-
mated study completion date is March 2015.
Combination with irinotecan-based chemotherapy
Second line
An  open-label,  randomized,  multicenter,  phase  III 
trial  compared  the  efficacy  of  panitumumab  plus 
chemotherapy versus chemotherapy alone in patients 
with previously treated mCRC.32 This trial included 
1186 patients who had progressed to a first-line flu-
oropyrimidine-based    chemotherapy.  These  patients 
were randomized to receive FOLFIRI (180 mgr/m2 
irinotecan + 400 mgr/m2 leucovorin + 400 mgr/m2 
folinic acid in bolus plus 2400 mgr/m2 of 5-flurouracil 
in continuous infusion) alone versus panitumumab 
6.0 mgr/kgr plus FOLFIRI. KRAS mutational status 
was assessed after the recruitment. The objective of 
this study was to evaluate improvements of PFS and 
OS with the addition of panitumumab to FOLFIRI 
as  second-line  therapy  for  mCRC.  The  secondary 
end points were objective response rate, duration of 
response, safety (including the incidence of AEs) and 
patient-reported outcomes.
For the primary analysis of PFS in the WT KRAS 
population,  the  addition  of  panitumumab  to  che-
motherapy  resulted  in  a  statistically  significant 
improvement in PFS (HR = 0.73, 95% CI 0.59–0.90, 
P = 0.004). Median PFS was 5.9 months (95% CI, 
5.5–6.7  months)  for  panitumumab-FOLFIRI  and 
3.9 months (95% CI, 3.7–5.3 months) for FOLFIRI 
alone.  In  the  MT  KRAS  patients,  there  was  no López-Gómez et al
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  statistically significant difference in PFS (HR = 0.85, 
95% CI 0.68–1.06, P = 0.14). The median PFS was 
5.0 months for the panitumumab-FOLFIRI group and 
4.9 months (95% CI, 3.6–5.6 months for the   FOLFIRI 
alone group.
There was no statistically significant difference in 
OS in the WT KRAS subpopulation (HR = 0.85, 95% CI 
0.70–1.04, P = 0.12). The median OS was 14.5 months 
(95% CI, 13.0–16.0 months) for the panitumumab-
FOLFIRI group and 12.5 months (95% CI, 11.2–14.2 
months)  for  the  FOLFIRI  alone  group.  In  the  MT 
KRAS group, the median OS was 11.8 months (95% 
CI, 10.4–13.3 months) for the panitumumab-FOLFIRI 
subgroup and 11.1 months (95% CI, 10.3–12.4 months) 
for the FOLFIRI alone subgroup. In patients with WT 
KRAS, the objective response rate was 35% (95% 
CI,  30%–41%)  in  the  panitumumab-FOLFIRI  arm 
versus 10% (95% CI, 7%–14%) in the FOLFIRI arm. 
In patients with MT KRAS, there were no differences 
in RR (13% for panitumumab-FOLFIRI versus 14% 
for FOLFIRI alone). Skin toxicity was the most fre-
quent AE reported.
This study has special relevance, as it was the first 
trial to analyze the treatment effect of an anti-EGFR 
therapy according to tumor KRAS mutational status. 
In this trial, the addition of panitumumab to FOLFIRI 
reduced the risk of progression or death in 27% of 
the WT KRAS population (P = 0.004). This result is 
important in the treatment of mCRC, as these results 
are  similar  to  the  previous  second-line  study  that 
evaluated the benefits of cetuximab addition to irino-
tecan (350 mgr/m2) in second-line therapy.40
Even though the effect on OS was not statistically 
significant in the WT KRAS population, the RR of 
35% is the highest reported in a randomized phase III 
second-line study (RR for irinotecan-based regimens 
are generally between 4% and 16%, independent of 
KRAS status).41 Considering the high response rate 
seen with panitumumab-FOLFIRI, this regimen may 
be of particular value in those patients who experience 
disease progression during first-line therapy. This reg-
imen might be of particular interest if patients present 
with potentially resectable metastases or symptom-
atic  disease,  due  to  its  good  results  in  controlling 
the response rate. Although no benefit was shown in 
patients with MT KRAS tumors, the addition of pani-
tumumab to FOLFIRI did not result in a decrease of 
OS in contrast to what was observed in other studies 
with panitumumab in combination with oxaliplatin 
therapy.31 The panitumumab and FOLFIRI combina-
tion has an acceptable safety profile, with skin toxic-
ity and hypomagnesemia being more frequent with 
the use of panitumumab and diarrhea secondary to 
both EGFR inhibitor and irinotecan. The incidence of 
panitumumab-related infusion reactions is ,1%.
Another phase II, open-label, single arm study 
was performed to evaluate the benefits of adding 
panitumumab to FOLFIRI in patients who had pro-
gressed  to  oxaliplatin  and  bevacizumab  first-line 
treatment.42 The efficacy endpoints were objective 
RR, PFS and OS, and the safety endpoints were the 
incidence of AEs. All of the endpoints were evalu-
ated by KRAS tumor status. The median PFS was 23 
weeks (95% CI 19–33 weeks) in patients with WT 
KRAS tumors and 19 weeks (95% CI 12–25 weeks) 
in  patients  with  MT  KRAS  tumors  patients.  The 
median OS was 50 weeks (95% CI 39–76 weeks) 
and 31 weeks (95% CI 23–47 weeks) respectively. 
Overall panitumumab improved RR, PFS and OS in 
KRAS WT patients.
Therefore, the results of these phase II and phase III 
trials have demonstrated the efficacy of panitumumab 
when added to FOLFIRI in previously treated mCRC 
patients.  In  addition,  this  regimen  has  a  convenient 
administration schedule and a manageable toxicity pro-
file, thereby representing an important new treatment 
option in second-line treatment of WT KRAS patients.
First-line therapy 
An  ongoing  first—line,  single-arm,  phase  II  study 
is  evaluating  the  benefits  of  adding  panitumumab 
to  first-line  FOLFIRI  treatment.43  KRAS  is  being 
prospectively  evaluated,  and  the  primary  endpoint 
is objective RR. This combination seems also well-
tolerated in this first-line setting, although the study 
is still ongoing.
Other settings
Panitumumab is also being studied in the peri-operative 
setting prior to liver metastases resection,44 but the results 
from randomized trials are still not   available. There is a 
single-arm, multicenter, phase II study of panitumumab 
in combination with capecitabine/  oxaliplatin in first-line 
WT KRAS cancer patients45 whose primary endpoint is 
the objective response rate with the   combination. The 
study is currently recruiting patients.panitumumab treatment in metastatic colorectal cancer
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As seen in this review and in contrast to cetuximab 
therapy,  the  addition  of  panitumumab  to  first-line 
FOLFOX4 treatment in untreated WT KRAS mCRC 
patients significantly improves PFS. The results of a 
recent summary of clinical safety results of panitu-
mumab in combination with chemotherapy from 5 
clinical trials in 823 patients indicates the combina-
tion is generally well-tolerated.46 This treatment rep-
resents a new therapeutic option for the treatment of 
patients with WT KRAS mCRC.
Ongoing trials
Numerous studies are currently evaluating the role 
of panitumumab in different settings. The VOLFI 
phase II study is recruiting patients to test the com-
bination of FOLFOXIRI and panitumumab vs. pan-
itumumab monotherapy in untreated patients with 
mCRC.47 Another phase II trial is assigning patients 
to receive mFOLFOX6 in combination with pani-
tumumab or bevacizumab48 every two weeks, and 
antibodies  are  also  being  assessed  in  combina-
tion with oxaliplatin and capecitabine every three 
weeks.39 For patients with chemorefractory tumors, 
panitumumab is being tested in several phase III 
trials administered as a single agent vs. BSC49 vs. 
cetuximab50  and  in  combination  with  irinotecan-
based chemotherapy.51
panitumumab
Considering the favorable results achieved in the pre-
viously noted randomized controlled trials, treatment 
with anti-EGFR inhibitors is recommended until pro-
gression.52  Nevertheless,  we  do  not  have  any  data 
to  support  the  post-progression  use  of  anti-EGFR. 
  Certain physicians support this approach, while others 
treat their patients until the best response is achieved 
and stop treatment until progression occurs. If the 
patient presents with severe toxicity, this “stop and 
go” intermittent therapy is especially preferred.53
Nevertheless, some case reports indicate that long-
term  responses  are  possible  during  panitumumab 
therapy. With a low toxicity,54 this agent may be an 
option for long-term treatment of selected patients. 
In  this  setting,  grade  3  cutaneous  toxicity  is  the 
most  frequently  observed  adverse  event,  and  the 
incidence increases with the duration of the therapy. 
Nevertheless,  cutaneous  toxicity  can  be  managed 
with   doxycycline in addition to topical steroids, oily 
cream and   levocetirizine hydrochloride in cases of 
intolerable itching. We still do not know the optimal 
management strategy for patients with mCRC. When 
a  patient  progresses  to  a  first-line  treatment  and 
responds  to  panitumumab  therapy,  the  prognosis 
might be improved by the addition of a panitumumab 
maintenance treatment, secondary to achieving better 
control of the disease. One of the reasons physicians 
tend  to  discontinue  panitumumab  treatment  is  the 
appearance  of  dermatological  toxicities.  However, 
the  toxicities  seen  with  these  agents  are  usually 
mild.    Skin-related  toxicities  are  well-managed  by 
physicians,  and  diarrhea  is  also  easily  controlled. 
Moreover,  infusion  reactions  are  extremely  rare 
during the treatment, due to the fully human nature 
of the antibody.
Therefore, although clinical daily practice supports 
the use of panitumumab during long-term therapy, 
there are no clinical trials to confirm its   superiority 
when  it  is  used  with  the  “stop  and  go”  treatment 
  strategy. Efforts should be made to identify the   factors 
associated with response to anti-EGFR therapy. The 
identification  of  these  potential  biomarkers  could 
be of great help in selecting those patients who are 
likely to benefit most from treatment with anti-EGFR 
antibodies.
•  Panitumumab is a fully human IgG2 monoclonal 
antibody that is highly selective for the EGFR. 
Skin rash and diarrhea are the most frequent AEs 
reported. Infusion reactions are extremely rare.
•  Panitumumab has only demonstrated activity in 
the  treatment  of  EGFR-expressing  mCRC  with 
WT KRAS.
•  Panitumumab  has  shown  an  important  clinical 
benefit in mCRC patients who have progressed to 
oxaliplatin and irinotecan-based chemotherapy.
•  According to the EMA, panitumumab is indicated 
as monotherapy after the failure of irinotecan- and 
oxaliplatin fluoropyrimidine-containing treatment 
regimens for mCRC.
•  Two recent phase III trials have shown that pani-
tumumab is associated with a clinical benefit in 
combination with oxaliplatin-based chemotherapy 
in  first-line  treatment  and  with  irinotecan-based 
chemotherapy in second-line therapy.
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•  On June 2011, the Committee for Human Medicinal 
Products  for  Human  Use  (CHMP)  adopted  two 
new indications for panitumumab:
○  In  first-line  therapy  in  combination  with 
FOLFOX
○  In  second-line  therapy  in  combination  with 
FOLFIRI for patients who had received first-
line fluoropyrimidine-based therapy (excluding 
irinotecan).
•  The PEAK study will attempt to clarify whether 
panitumumab or bevacizumab is the best option 
for first-line WT KRAS mCRC patients.
•  Panitumumab combinations with capecitabine are 
currently being researched.
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